These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 4596671)

  • 1. The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients.
    McClelland HA; Blessed G; Bhate S; Ali N; Clarke PA
    Br J Psychiatry; 1974 Feb; 124(579):151-9. PubMed ID: 4596671
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter: Abrupt withdrawal of antiparkinsonian drugs in chronic schizophrenic patients.
    McLelland HA; Blessed G; Bhate S
    Br J Psychiatry; 1974 Nov; 125():514-5. PubMed ID: 4461148
    [No Abstract]   [Full Text] [Related]  

  • 3. Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy.
    Hershon HI; Kennedy PF; McGuire RJ
    Br J Psychiatry; 1972 Jan; 120(554):41-50. PubMed ID: 4557435
    [No Abstract]   [Full Text] [Related]  

  • 4. [Withdrawal of antiparkinson drugs in long term neuroleptic treatment].
    Lerner J; Blum E; Fuchs I; Grinberg M
    Harefuah; 1978 Oct; 95(8):239-41. PubMed ID: 33879
    [No Abstract]   [Full Text] [Related]  

  • 5. Penfluridol: a long-acting oral neuroleptic as therapeutic agent in chronic schizophrenia.
    Jus A; Pineau R; Jus K; Villeneuve A; Gautier J; Pires P; Drolet A; Cote M; Villeneuve R
    Curr Ther Res Clin Exp; 1974 Oct; 16(10):1041-58. PubMed ID: 4215617
    [No Abstract]   [Full Text] [Related]  

  • 6. [Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
    Caroli F; Littre-Poirier MF; Ginestet D; Deniker P
    Encephale; 1975; 1(1):69-74. PubMed ID: 805695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurological consequences of psychotropic drug withdrawal in schizophrenic children.
    Polizos P; Engelhardt DM; Hoffman SP; Waizer J
    J Autism Child Schizophr; 1973; 3(3):247-53. PubMed ID: 4800390
    [No Abstract]   [Full Text] [Related]  

  • 8. Behavioral effects of drug therapy on psychogeriatric inpatients. I. Chlorpromazine and thioridazine.
    Altman H; Mehta D; Evenson RC; Sletten IW
    J Am Geriatr Soc; 1973 Jun; 21(6):241-8. PubMed ID: 4575803
    [No Abstract]   [Full Text] [Related]  

  • 9. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J; Rasmussen PT; Hansen L; Kristjansen P
    Acta Psychiatr Scand; 1977 Apr; 55(4):251-60. PubMed ID: 324238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of psychotropic drug use for schizophrenia.
    Laska E; Varga E; Wanderling J; Simpson G; Logemann GW; Shah BK
    Dis Nerv Syst; 1973; 34(6):294-305. PubMed ID: 4782286
    [No Abstract]   [Full Text] [Related]  

  • 11. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt?
    Manos N; Gkiouzepas J; Tzotzoras T; Tzanetoglou A
    J Nerv Ment Dis; 1981 Oct; 169(10):659-61. PubMed ID: 6116743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiparkinsonian prescription and extrapyramidal symptoms.
    Grover S; Kulhara P
    Br J Psychiatry; 2006 May; 188():492; author reply 492-3. PubMed ID: 16648544
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
    Park S; Ross-Degnan D; Adams AS; Sabin J; Kanavos P; Soumerai SB
    Br J Psychiatry; 2005 Aug; 187():137-42. PubMed ID: 16055824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline].
    Errichiello G; Maglione S
    Minerva Med; 1974 May; 65(41):2357-9. PubMed ID: 4602984
    [No Abstract]   [Full Text] [Related]  

  • 15. Noncompliance with antiparkinsonian medications in neuroleptic-treated schizophrenic patients: three cases of an unreported phenomenon.
    Bermanzohn PC; Siris SG
    J Clin Psychiatry; 1994 Nov; 55(11):488-91. PubMed ID: 7989282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rabbit syndrome and antiparkinsonian medication in schizophrenic patients.
    Wada Y; Yamaguchi N
    Neuropsychobiology; 1992; 25(3):149-52. PubMed ID: 1357583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antagonism between anti-Parkinson drugs and neuroleptics. Apropos of various withdrawal experiences, a personal one among them (2nd part)].
    Bourgeois M; Bouey P
    Ann Med Psychol (Paris); 1976 Nov; 2(4):669-708. PubMed ID: 1020864
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter: Fluphenazine with other antipsychotic drugs.
    Chouinard G; Fontaine R
    Am J Psychiatry; 1975 Jul; 132(7):760-1. PubMed ID: 1137032
    [No Abstract]   [Full Text] [Related]  

  • 19. Schizophrenic subtypes defined by response to drugs and placebo.
    Goldberg SC; Mattsson NB
    Dis Nerv Syst; 1968 May; 29(5):Suppl:153-8. PubMed ID: 4876985
    [No Abstract]   [Full Text] [Related]  

  • 20. Does thalamotomy alter the course of Parkinson's disease?
    Tasker RR; DeCarvalho GC; Li CS; Kestle JR
    Adv Neurol; 1996; 69():563-83. PubMed ID: 8615182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.